Peter van Mourik

61 Potentiator synergy in rectal organoids 48. Ren, X.-Q. et al. Function of the ABC signature sequences in the human multidrug resistance protein 1. Mol. Pharmacol. 65, 1536–1542 (2004). 49. Lin, W.-Y., Jih, K.-Y. & Hwang, T.-C. A single amino acid substitution in CFTR converts ATP to an inhibitory ligand. J. Gen. Physiol. 144, 311–320 (2014). 50. Veit, G. et al. Some gating potentiators, including VX-770, diminish ΔF508- CFTR functional expression. Sci Transl Med 6, 246ra97 (2014). 51. Cholon, D. M. et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med 6, 246ra96 (2014). 52. Clancy, J. P. et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67 : 12–8 (2012). 53. Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807–818 (2007). 54. Yang, Z., Kulkarni, K., Zhu, W. & Hu, M. Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem 12, 1264–1280 (2012). 55. Strimpakos, A. S. & Sharma, R. A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signal. 10, 511–545 (2008). 56. De Boeck, K. et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J. Cyst. Fibros. 10 Suppl 2, S53–66 (2011). 57. de Jonge, H. R. et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J. Cyst. Fibros. 3 Suppl 2, 159–163 (2004). 3